文献速递产科母胎医学

高血压孕妇中sFlt-1/PlGF比值诊断子痫前期的阈值

sFlt-1/PlGF ratio thresholds for diagnosing pre-eclampsia in pregnant women with high blood pressure.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-09-24

本单中心前瞻性观察性队列研究纳入中国南方一家三级医院2020年1月至2023年12月间24+0至38+6周妊娠、合并高血压的单胎孕妇1329例,分为推导队列(n=814)和验证队列(n=515)。推导队列确定预测1周内早发型和晚发型子痫前期的sFlt-1/PlGF比值阈值分别为74和95,验证队列中≥74预测早发型子痫前期的敏感度为87.7%、特异度为97.0%,≥95预测晚发型子痫前期的敏感度为36.5%、特异度为95.0%,且两阈值均与不良母儿结局风险增加相关。

要点

  • 推导队列确定sFlt-1/PlGF比值预测1周内早发型子痫前期阈值为74、晚发型为95。
  • 验证队列中≥74预测早发型子痫前期敏感度87.7%、特异度97.0%。
  • 验证队列中≥95预测晚发型子痫前期敏感度36.5%、特异度95.0%。

核心结论

  • 在24+0至38+6周妊娠的高血压单胎孕妇中,验证的sFlt-1/PlGF比值预测1周内早发型和晚发型子痫前期的阈值分别为74和95。
  • sFlt-1/PlGF比值≥74和≥95与不良母儿结局风险增加相关,提示这些阈值可用于中国单胎高血压孕妇的风险分层。

研究设计与样本

  • 单中心、前瞻性、观察性队列研究,在中国南方一家三级医院开展,研究时间为2020年1月至2023年12月。
  • 纳入24+0至38+6周妊娠、合并高血压(收缩压≥140 mmHg和/或舒张压≥90 mmHg)的单胎孕妇1329例,均具备完整随访记录。
  • 按入组日期分为推导队列(n=814,61.2%)和验证队列(n=515,38.8%),两队列sFlt-1/PlGF测量后1周内子痫前期发生率分别为35.5%和38.6%(P=0.267)。

主要发现

  • 推导队列通过受试者工作特征曲线分析确定sFlt-1/PlGF比值预测早发型子痫前期(诊断<34周)的最佳阈值为74,预测晚发型子痫前期(诊断≥34周)的最佳阈值为95。
  • 验证队列中,sFlt-1/PlGF比值≥74预测生物标志物测量后1周内早发型子痫前期的敏感度为87.7%(95% CI,77.9-94.2%),特异度为97.0%(95% CI,91.6-99.4%)。
  • 验证队列中,sFlt-1/PlGF比值≥95预测1周内晚发型子痫前期的敏感度为36.5%(95% CI,28.1-45.6%),特异度为95.0%(95% CI,91.0-97.4%)。
  • 在推导队列和验证队列中,sFlt-1/PlGF比值≥74(测量时孕周<34周)和≥95(测量时孕周≥34周)均显著预测不良母儿结局。

关键数值与推荐

  • 预测1周内早发型子痫前期(诊断<34周)的sFlt-1/PlGF比值阈值为74。
  • 预测1周内晚发型子痫前期(诊断≥34周)的sFlt-1/PlGF比值阈值为95。

临床怎么用

  • 原文结论提示,sFlt-1/PlGF比值阈值74和95可用于中国单胎高血压孕妇的风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: An imbalance between soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) is characteristic of the progression of hypertensive disorder of pregnancy (HDP) to pre-eclampsia (PE). Monitoring the sFlt-1/PlGF ratio to determine whether HDP progresses to PE can aid clinical management and decision-making. This study aimed to determine the diagnostic thresholds of the sFlt-1/PlGF ratio for early-onset and late-onset PE in pregnant Chinese women with high blood pressure. METHODS: This single-center, prospective, observational cohort study was conducted among pregnant women with high blood pressure (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg) at a tertiary hospital in Southern China, from January 2020 to December 2023. Women with a singleton pregnancy and complete follow-up records were assigned to the derivation cohort or the validation cohort depending on their date of enrolment. Initial cut-offs of the sFlt-1/PlGF ratio to predict the development of early-onset or late-onset PE within 1 week after biomarker measurement were determined using receiver-operating-characteristics-curve analysis in the derivation cohort. This analysis was performed separately for pregnancies with gestational age (GA) < 34 weeks and those with GA ≥ 34 weeks at the time of biomarker measurement. Subsequently, the derived cut-offs were validated in the validation cohort. The rate of adverse maternal and perinatal outcomes was compared according to whether the sFlt-1/PlGF ratio was above or below the validated cut-off, stratified by GA at biomarker measurement, in both the derivation and validation cohorts. RESULTS: A total of 1329 women with a singleton pregnancy complicated by high blood pressure, presenting between 24 + 0 and 38 + 6 weeks' gestation, were recruited during the study period. Participants were stratified into the derivation (n = 814 (61.2%)) and validation (n = 515 (38.8%)) cohorts, which had comparable PE incidence within 1 week after sFlt-1/PlGF measurement (35.5% vs 38.6%, respectively; P = 0.267). In the derivation cohort, the optimal sFlt-1/PlGF ratio cut-offs were determined to be 74 for predicting early-onset PE (diagnosis < 34 weeks) and 95 for predicting late-onset PE (diagnosis ≥ 34 weeks). In the validation cohort, the predetermined sFlt-1/PlGF ratio cut-off of ≥ 74 showed a sensitivity of 87.7% (95% CI, 77.9-94.2%) and a specificity of 97.0% (95% CI, 91.6-99.4%) for predicting early-onset PE within 1 week after biomarker measurement, while a sFlt-1/PlGF ratio of ≥ 95 demonstrated a sensitivity of 36.5% (95% CI, 28.1-45.6%) and a specificity of 95.0% (95% CI, 91.0-97.4%) for the prediction of late-onset PE within 1 week. Additionally, these ratios (≥ 74 for GA < 34 weeks and ≥ 95 for GA ≥ 34 weeks at biomarker measurement) significantly predicted adverse maternal and perinatal outcomes in both cohorts. CONCLUSIONS: In pregnant women with high blood pressure presenting between 24 + 0 and 38 + 6 weeks' gestation, the validated sFlt-1/PlGF ratio cut-offs for predicting early-onset PE and late-onset PE diagnosis within 1 week after biomarker measurement were 74 and 95, respectively. Furthermore, sFlt-1/PlGF ratios ≥ 74 and ≥ 95 were associated with increased risks of adverse maternal and perinatal outcomes, suggesting clinical utility for these cut-offs for risk stratification in Chinese women with a singleton pregnancy and high blood pressure. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pan X, Peng J, Chen Y, et al. sFlt-1/PlGF ratio thresholds for diagnosing pre-eclampsia in pregnant women with high blood pressure. Ultrasound Obstet Gynecol. 2025. PMID: 40992360. doi:10.1002/uog.70075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。